| abstract |
The present invention relates generally to methods, devices and compositions for treating mental, neurological, and cognitive diseases related to deficiencies in the biosynthesis and/or metabolism of neurotransmitters, wherein the neurotransmitter is acetylcholine, nitric oxide, histamine, norepinephrine, a bioactive amine, an amino acid or a neuropeptide, veratridine, curare, tetrodotoxin, f lunarizine, calσicludine, and omega -cono toxin; wherein the bioactive amine is selected from the group consisting of dopamine, epinephrine, norepinephrine, serotonin; wherein the amino acid is selected from the group consisting of glutamate, glycine and gamma- aminobutyric acid (GABA) ; the neuropeptide is selected from the group consisting of enkephalins, dynorphins and substance P and the psychological disorder is selected from the group consisting of addiction, substance abuse, autism, dyslexia, obsessive- compulsive disorder, generalized anxiety disorder, post- traumatic stress disorder, panic attacks, social phobia, major depression, bipolar disorder and schizophrenia, tardive dyskinesia, Huntington's disease, and Parkinson's disease. |